Recent Posts

• SPIL Q4FY26 Financial Results
• Press Release Sun Pharma reports Q4 & full year results for FY26
• Sun Pharma signs Definitive Agreement to Acquire Organon
• Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India
• Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis